ALTO vs FCX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALTO's deterministic health scores reveal significant concerns: a Piotroski F-Score of 2/9 indicates weak financial health, and the absence of an Altman Z-Score raises distress risk concerns. Despite this, the stock trades at a discount to its Graham Number ($3.38) and intrinsic value ($1.12), suggesting potential undervaluation. The recent earnings surprise history is volatile but highly positive in the most recent quarters, with a 75% Q/Q EPS growth and 149% YoY EPS growth. Strong price momentum—253% 1-year return and 294.9% 6-month return—reflects market optimism, supported by a strong-buy analyst consensus. However, the company's negative revenue growth (-1.90% YoY) and minimal profitability (1.45% profit margin) remain critical red flags. Price trades at a 37.9% premium to fair value estimate ($3.38), limiting near-term upside from a valuation perspective.
FCX shows bearish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
ALTO vs FCX: Head-to-Head Comparison
This page compares Alto Ingredients, Inc. (ALTO) and Freeport-McMoRan Inc. (FCX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.